A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia

Area of Science:

• Immunology
• Oncology
• Transplantation

Background:

• Minor histocompatibility antigens (mHags) are crucial for anti-leukemia immune responses after allogeneic bone marrow transplantation (BMT).
• However, mHags are often expressed on normal tissues, leading to graft-versus-host disease (GVHD).
• Targeting leukemia-specific antigens is essential to separate anti-leukemia effects from GVHD.

Purpose of the Study:

• To identify and characterize a novel minor histocompatibility antigen (mHag) involved in anti-leukemia immunity.
• To investigate the specificity and potential therapeutic application of this novel mHag in B-cell acute lymphoblastic leukemia (B-ALL).

Main Methods:

• Identification of a novel mHag, HB-1, in a patient with B-ALL post-HLA-matched BMT.
• Characterization of the gene encoding the HB-1 peptide and its expression profile.
• Analysis of CTL recognition of the HB-1 peptide, including the role of a specific polymorphism and HLA association.

Main Results:

• A novel mHag, HB-1, was identified, eliciting donor-derived cytotoxic T lymphocyte (CTL) reactivity against B-ALL.
• The HB-1 gene encodes the peptide EEKRGSLHVW, recognized in association with HLA-B44.
• HB-1 expression is restricted to B-ALL cells and Epstein-Barr virus-transformed B cells, with a critical polymorphism affecting CTL recognition.

Conclusions:

• The novel HB-1 antigen offers a leukemia-specific target for immunotherapy.
• HB-1-specific CTLs can be generated in vitro, presenting a promising strategy for B-ALL treatment.
• Targeting HB-1 may allow for specific immune attack on B-ALL, minimizing the risk of GVHD.